Interleukin Genetics Company Profile (OTCMKTS:ILIU)

About Interleukin Genetics (OTCMKTS:ILIU)

Interleukin Genetics logoInterleukin Genetics, Inc. develops and markets genetic tests for chronic diseases and health-related conditions. The Company operates through the genetic test business segment. The Company's products include PerioPredict genetic test and Inherent Health line of genetic tests. PerioPredict is a genetic risk test that analyzes genetic variations associated with inflammation and identifies individuals with a life-long predisposition to over-produce inflammation. PerioPredict identifies specific polymorphisms (genetic variations) in genes that regulate the production of interleukin-1 cytokines. PerioPredict identifies adults at increased risk for severe periodontal disease. The Company markets additional genetic tests through its Inherent Heath brand. Its additional genetic tests include weight management genetic test, bone health genetic test, heart health genetic test, nutritional needs genetic test and wellness select genetic test.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:ILIU
  • CUSIP: N/A
  • Web: www.ilgenetics.com
Capitalization:
  • Market Cap: $2.8 million
  • Outstanding Shares: 229,471,000
Average Prices:
  • 50 Day Moving Avg: $0.04
  • 200 Day Moving Avg: $0.09
  • 52 Week Range: $0.01 - $0.25
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.60
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $1.75 million
  • Price / Sales: 1.57
  • Book Value: ($0.02) per share
  • Price / Book: -0.55
Profitability:
  • EBIDTA: ($7,370,000.00)
  • Net Margins: -481.82%
  • Return on Assets: -237.71%
Debt:
  • Debt-to-Equity Ratio: -0.16%
  • Current Ratio: 0.23%
  • Quick Ratio: 0.22%
Misc:
  • Average Volume: 96,764 shs.
  • Beta: 1.35
  • Short Ratio: 4
 
Frequently Asked Questions for Interleukin Genetics (OTCMKTS:ILIU)

What is Interleukin Genetics' stock symbol?

Interleukin Genetics trades on the OTCMKTS under the ticker symbol "ILIU."

How were Interleukin Genetics' earnings last quarter?

Interleukin Genetics Inc. (OTCMKTS:ILIU) issued its quarterly earnings results on Friday, May, 12th. The company reported ($0.01) earnings per share (EPS) for the quarter. The business earned $0.20 million during the quarter. View Interleukin Genetics' Earnings History.

Who are some of Interleukin Genetics' key competitors?

Who are Interleukin Genetics' key executives?

Interleukin Genetics' management team includes the folowing people:

  • James M. Weaver, Independent Chairman of the Board
  • Kenneth S. Kornman Ph.D. DDS, President, Chief Scientific Officer, Director
  • Mark B. Carbeau, Chief Executive Officer, Director
  • Stephen J. DiPalma, Interim Chief Financial Officer
  • Stephan Toutain, Chief Commercial Officer
  • Lionel Carnot, Independent Director
  • Joseph M. Landstra, Independent Director
  • William C. Mills III, Independent Director
  • Dayton C. Misfeldt, Independent Director

How do I buy Interleukin Genetics stock?

Shares of Interleukin Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Interleukin Genetics' stock price today?

One share of Interleukin Genetics stock can currently be purchased for approximately $0.01.


MarketBeat Community Rating for Interleukin Genetics (OTCMKTS ILIU)
Community Ranking:  3.1 out of 5 (  )
Outperform Votes:  5 (Vote Outperform)
Underperform Votes:  3 (Vote Underperform)
Total Votes:  8
MarketBeat's community ratings are surveys of what our community members think about Interleukin Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Interleukin Genetics (OTCMKTS:ILIU) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Interleukin Genetics (OTCMKTS:ILIU)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Interleukin Genetics (OTCMKTS:ILIU)
Earnings by Quarter for Interleukin Genetics (OTCMKTS:ILIU)
Earnings History by Quarter for Interleukin Genetics (OTCMKTS ILIU)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/12/2017Q1 2017($0.01)$0.20 millionViewN/AView Earnings Details
11/15/2016Q3 2016($0.01)$0.73 millionViewN/AView Earnings Details
8/15/2016Q2($0.01)($0.01)$0.25 million$0.59 millionViewListenView Earnings Details
5/12/2016Q1($0.01)($0.01)$0.27 million$0.96 millionViewListenView Earnings Details
3/17/2016Q4($0.01)($0.01)$0.31 million$0.37 millionViewListenView Earnings Details
11/12/2015Q3($0.01)($0.01)$0.36 million$0.30 millionViewN/AView Earnings Details
8/14/2015($0.01)($0.01)ViewN/AView Earnings Details
8/14/2015Q2($0.01)($0.01)$0.37 million$0.38 millionViewListenView Earnings Details
3/20/2015Q4 2014($0.01)($0.01)$0.52 million$0.32 millionViewN/AView Earnings Details
11/14/2014Q3 2014($0.01)($0.01)$0.58 million$0.47 millionViewN/AView Earnings Details
8/13/2014Q2 2014($0.01)($0.01)$0.47 million$0.53 millionViewN/AView Earnings Details
3/20/2014Q4 13($0.01)($0.02)$0.54 million$0.67 millionViewN/AView Earnings Details
11/14/2013Q3($0.01)($0.02)ViewListenView Earnings Details
8/14/20132Q13($0.02)ViewN/AView Earnings Details
3/28/2013Q4 12($0.03)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Interleukin Genetics (OTCMKTS:ILIU)
Current Year EPS Consensus Estimate: $-0.03 EPS
Next Year EPS Consensus Estimate: $-0.02 EPS

Dividends

Dividend History for Interleukin Genetics (OTCMKTS:ILIU)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Interleukin Genetics (OTCMKTS:ILIU)
Insider Ownership Percentage: 54.40%
Institutional Ownership Percentage: 0.27%
Insider Trades by Quarter for Interleukin Genetics (OTCMKTS:ILIU)
Insider Trades by Quarter for Interleukin Genetics (OTCMKTS:ILIU)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/29/2016Bay City Capital Fund V, L.P.Major ShareholderBuy30,181,086$0.10$3,018,108.60View SEC Filing  
7/29/2016Kenneth S. KornmanInsiderBuy25,150$0.10$2,515.00View SEC Filing  
7/29/2016Stephen J DipalmaCFOBuy100,603$0.10$10,060.30View SEC Filing  
12/23/2014Bay City Capital LlcMajor ShareholderBuy26,491,952$0.10$2,649,195.20View SEC Filing  
12/23/2014Stephen J DipalmaCFOBuy249,252$0.10$24,925.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Interleukin Genetics (OTCMKTS:ILIU)
Latest Headlines for Interleukin Genetics (OTCMKTS:ILIU)
Source:

Social

Chart

Interleukin Genetics (ILIU) Chart for Tuesday, July, 25, 2017

This page was last updated on 7/25/2017 by MarketBeat.com Staff